{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:08:13Z","timestamp":1779433693423,"version":"3.53.1"},"reference-count":38,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"5","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: To investigate serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP), insulin-like growth factor binding protein-7 (IGFBP-7), and C1q tumour necrosis factor-related protein 12 (CTRP12) levels and significance in patients with chronic heart failure (CHF). Methods: The CHF group consisted of 116 CHF patients who received care at this hospital between October 2023 and March 2025. The patients were classified into Grade II (47 patients), Grade III (41 patients), or Grade IV (28 patients) based on the heart function classification of the New York Heart Association (NYHA). The control group consisted of 64 healthy patients who were physically examined in the hospital during the same period. Using multivariate logistic regression, the factors impacting MACEs in patients with congestive heart failure were examined. Through the use of the receiver operating characteristic (ROC) curve, researchers were able to assess the predictive power of blood NT-pro-BNP IGFBP-7, and CTRP12 for MACEs in chronic heart failure patients. Results: Comparing the CHF group to the control group, the LVEDD increased, the LVEF and serum CTRP12 decreased, and the levels of NT-pro-BNP, IGFBP-7, Hcy, and hs-CRP climbed (P&amp;lt; 0.05). Among patients with CHF of different grades, serum NT-pro-BNP IGFBP-7, Hcy, hs-CRP and LVEDD levels were all lower in Grade II patients than in Grade III patients. Furthermore, the differences between any two grades were statistically significant (P&amp;lt; 0.05). The levels of LVEF and serum CTRP12 in the MACE group decreased, the LVEDD increased, and the levels of serum Hcy, hs-CRP NT-pro-BNP and IGFBP-7 increased (P&amp;lt; 0.05). MACEs in CHF patients were influenced by serum NT-pro-BNP IGFBP-7, and CTRP12 (P&amp;lt; 0.05). The areas under the curve (AUCs) of serum NT-pro-BNP IGFBP-7, CTRP12 alone and the combination of the three for predicting MACEs in patients with CHF were 0.862 (95% CI: 0.786-0.919), 0.805 (95% CI: 0.721-0.872), and 0.860 (95% CI: 0.784-0.918) and 0.961 (95% CI: 0.908-0.988), respectively. The AUCs of the three combined predictions were significantly greater than those of the individual predictions of NT-pro-BNP IGFBP-7, and CTRP12 (Z = 3.050 , 3.883, 3.218, all P&amp;lt; 0.05). Conclusions: Serum levels of IGFBP-7 and NT-pro-BNP increase in CHF patients, whereas the level of CTRP12 decreases. Additionally, once functional classification was applied, NT-pro-BNP IGFBP-7, and CTRP12 levels changed. The combined detection of these three parameters has better efficacy in predicting MACEs in patients with CHF.<\/jats:p>","DOI":"10.5937\/jomb0-61393","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:09:12Z","timestamp":1762762152000},"page":"1014-1022","source":"Crossref","is-referenced-by-count":0,"title":["Correlation analysis of Serum NT-pro-BNP, IGFBP-7 and CTRP12 levels in chronic heart failure patients"],"prefix":"10.5937","volume":"45","author":[{"given":"Zhen","family":"Fan","sequence":"first","affiliation":[{"name":"The Affiliated Chuzhou Hospital of Anhui Medical University, Department of Cardiology, Chuzhou City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Huang","sequence":"additional","affiliation":[{"name":"Western Theatre Command Air Force Hospital, Department of Laboratory Medicine, Chengdu City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laoji","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University, Department of Cardiology, Hefei City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jierou","family":"Yan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University, Department of Cardiology, Hefei City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Xiaoshan District, Department of Cardiology, Hangzhou City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Dogheim GM, Amralla MT, Werida RH. The clinical significance of neopterin and NT-pro BNP in chronic heart failure: a systematic review. Acta Cardiol 2024; 79(6): 720-9. doi: 10.1080\/00015385.2024.2371628. Epub 2024 Jun 27. PMID: 38934779;","DOI":"10.1080\/00015385.2024.2371628"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hendricks S, Dykun I, Balcer B, Totzeck M, Rassaf T, Mahabadi AA. Higher BNP\/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. ESC Heart Fail 2022; 9(5): 3198-209. doi: 10.1002\/ehf2.14019. Epub 2022 Jun 29. PMID: 35769032; PMCID: PMC9715818;","DOI":"10.1002\/ehf2.14019"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Zheng Y, Huang C, Zhang W, Shi Y, Chen F, Zhou J. Traditional Chinese medicine as an adjunctive therapy improves cardiac function and reduces serum inflammatory markers in patients with chronic heart failure. J Med Biochem 2025; 44(3): 507-14. DOI: 10.5937\/jomb0-54440;","DOI":"10.5937\/jomb0-54440"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Militaru M, Lighezan DF Tudoran C, Tudoran M, Militaru AG. Factors influencing the development and severity of cognitive decline in patients with chronic heart failure. Medicina (Kaunas) 2024; 60(11): 1859. doi: 10.3390\/medicina60111859. PMID: 39597044; PMCID: PMC11596752;","DOI":"10.3390\/medicina60111859"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Moscucci F Sciomer S, Maffei S, Meloni A, Lospinuso I, Carnovale M, et al. Sex differences in repolarisation markers: telemonitoring for chronic heart failure patients. J Clin Med 2023; 12(14): 4714. doi: 10.3390\/jcm12144714. PMID: 37510828; PMCID: PMC10381165;","DOI":"10.3390\/jcm12144714"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dattilo G, Bitto R, Correale M, Morabito C, Vaccaro V, Laterra G, et al. Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril\/valsartan: a real-life experience. Minerva Cardiol Angiol 2022; 70(5): 555-62. doi: 10.23736\/S2724-5683.20.05494-8. Epub 2021 Apr 7. PMID: 33823573;","DOI":"10.23736\/S2724-5683.20.05494-8"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chen W, Luo X , Li W, Li X, Wang Y Zhang R, et al. Uncovering the active ingredients of Xinbao pill against chronic heart failure: a chemical profiling, pharmacokinetics and pharmacodynamics integrated study. J Ethnopharmacol 2025; 342: 119418. doi: 10.1016\/j.jep.2025.119418. Epub 2025 Jan 27. PMID: 39880064;","DOI":"10.1016\/j.jep.2025.119418"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Naser N, Kulic M, Jatic Z. Our experience with sacubitril\/valsartan in chronic heart failure management-HFrEF in the ambulatory setting. Med Arch 2022; 76(2): 101-7. doi: 10.5455\/medarh.2022.76.101-107. PMID: 35774049; PMCID: PMC9233466;","DOI":"10.5455\/medarh.2022.76.101-107"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Sharma S, Mathur D, Goswami S, Gupta MK, Bhardwaj P Kumar P et al. Prevalence of periodontitis in chronic heart failure patients and its relationship with NT-proBNP: a cross-sectional study. Indian Heart J 2025; 77(2): 110-3. doi: 10.1016\/j.ihj.2025.03.004. Epub 2025 Mar 7. PMID: 40057232; PMCID: PMC12138112;","DOI":"10.1016\/j.ihj.2025.03.004"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Feng ZF, Liu Y Salvador JT, Ala MB, Nery MAC, Huang XY, Zhang L, Liu S, et al. Implementation and evaluation of hospital-to-home transitional care intervention in patients with chronic heart failure. BMC Nurs 2025; 24(1): 717. doi: 10.1186\/s12912-025-03447-5. PMID: 40597265; PMCID: PMC12210740;","DOI":"10.1186\/s12912-025-03447-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Pages N, Picard F, Barritault F , Amara W, Lafitte S, Maribas P , et al. Remote patient monitoring for chronic heart failure in France: when an innovative funding program (ETAPES) meets an innovative solution (Satelia\u00ae Cardio). Digit Health 2022; 8: 20552076221116774. doi: 10.1777\/20552076221116774. PMID: 36034602; PMCID: PMC9403459;","DOI":"10.1177\/20552076221116774"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y Liu J, Luo R, Wu D, Xu P Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV\/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY) 2021; 13(8): 10833-52. doi: 10.18632\/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137;","DOI":"10.18632\/aging.202860"},{"key":"ref13","unstructured":"Lin ZB, Teng ZH, Xu YR, Deng YS, Liang GL, Deng HY, et al. Predictive value of whole blood cell derived inflammatory markers in combination with NT-proBNP on the prognosis of patients with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2025; 53(2): 143-50. Chinese. doi: 10.3760\/cma.j.cn112148-20241211-00774. PMID: 39965849;"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Adamson C, Welsh P Docherty KF de Boer RA, Diez M, Dro d J, et al. IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF JACC Heart Fail 2023; 11(3): 291-304. doi: 10.1016\/j.jchf.2022.09.004. Epub 2022 Nov 9. PMID: 36592046;","DOI":"10.1016\/j.jchf.2022.09.004"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Wu D, Xu P Ruan X , Yan J, et al. Immunomodulatory factor TIM3 of cytolytic active genes affected the survival and prognosis of lung adenocarcinoma patients by multi-omics analysis. Biomedicines 2022; 10(9): 2248. doi: 10.3390\/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572;","DOI":"10.3390\/biomedicines10092248"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wu L, Yang L, Qian X , Hu W, Wang S, Yan J. Mannan-decorated lipid calcium phosphate nanoparticle vaccine increased the antitumor immune response by modulating the tumor microenvironment. J Funct Biomater 2024; 15(8): 229. doi: 10.3390\/jfb15080229. PMID: 39194667; PMCID: PMC11355305;","DOI":"10.3390\/jfb15080229"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Molto-Balado P Revert\u00e9-Villarroya S, Monclus-Arasa C, Balado-Albiol MT, Baset-Mart\u00ednez S, Carot-Domenech J, et al. Heart failure and major adverse cardiovascular events in atrial fibrillation patients: a retrospective primary care cohort study. Biomedicines 2023; 11(7): 1825. doi: 10.3390\/biomedicines11071825. PMID: 37509465; PMCID: PMC10376826;","DOI":"10.3390\/biomedicines11071825"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Wu L, Liu Q, Ruan X , Luan X , Zhong Y, Liu J, et al. Multiple omics analysis of the role of RBM10 gene instability in immune regulation and drug sensitivity in patients with lung adenocarcinoma (LUAD). Biomedicines 2023; 11(7): 1861. doi: 10.3390\/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220;","DOI":"10.3390\/biomedicines11071861"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Du J, Yang L, Hao Z, Li H, Yang C, Wang X , et al. Development and validation of a nomogram for major adverse cardiovascular events after chronic total occlusion percutaneous coronary intervention for ischemic heart failure. Catheter Cardiovasc Interv 2024; 104(3): 451-61. doi: 10.1002\/ccd.31139. Epub 2024 Jul 20. PMID: 39033330;","DOI":"10.1002\/ccd.31139"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Aggarwal R, Bhatt DL, Szarek M, Cannon CP Leiter LA, Inzucchi SE, et al. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial. Lancet Diabetes Endocrinol 2025; 13(4): 321-32. doi: 10.1016\/S2213-8587(24)00362-0. Epub 2025 Feb 14. PMID: 39961315;","DOI":"10.1016\/S2213-8587(24)00362-0"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y Ruan X , Wu D, Xu P Liu J, et al. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs 2022; 33(1): e590-e603. doi: 10.1097\/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349;","DOI":"10.1097\/CAD.0000000000001189"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kavousi S, Hosseinpour A, Bahmanzadegan Jahromi F, Attar A. Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart failure: a meta-analysis of randomised controlled trials. J Transl Med 2024; 22(1): 786. doi: 10.1186\/s12967-024-05352-y PMID: 39174960; PMCID: PMC11342608;","DOI":"10.1186\/s12967-024-05352-y"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Le Gall L, Harambat J, Combe C, Philipps V, Proust-Lima C, Dussartre M, et al. Hemoglobin trajectories in chronic kidney disease and risk of major adverse cardiovascular events. Nephrol Dial Transplant 2024; 39(4): 669-82. doi: 10.1093\/ndt\/gfad235. PMID: 37935529;","DOI":"10.1093\/ndt\/gfad235"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Desingu R, Kaore S, Kandelwal G, Balakrishnan S. Evaluation of ivabradine plus beta-blocker versus beta-blocker alone in addition to standard care in reducing hospitalisation and major adverse cardiovascular event in patients with chronic heart failure: a prospective observational study in tertiary care hospital in central India. Egypt Heart J 2024; 76(1): 67. doi: 10.1186\/s43044-024-00500-7. PMID: 38819505; PMCID: PMC11143102;","DOI":"10.1186\/s43044-024-00500-7"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Yu X , Wu D, Xu P , Lv L, et al. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs 2022; 33(9): 943-59. doi: 10.1097\/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295;","DOI":"10.1097\/CAD.0000000000001319"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zhang L, Ou X , Lin J, Luo X , Zhou J, Zhou X , Zhao P , et al. Red blood cell membrane lipidomics: potential biomarkers detecting method for plasma volume overload and major adverse cardiovascular events in chronic heart failure patients. Adv Sci (Weinh) 2025; e02893. doi: 10.1002\/advs.202502893. Epub ahead of print. PMID: 40548468;","DOI":"10.1002\/advs.202502893"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, et al. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. Int J Bioprinting 2024; 10(1): 1256. doi: 10.36922\/ijb.1256;","DOI":"10.36922\/ijb.1256"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Wu L, Li X , Yan J. Commentary: machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol 2024; 45: 101995. doi: 10.1016\/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241;","DOI":"10.1016\/j.tranon.2024.101995"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Sulaiman S, Mohamed Khalafallah RA, Elbadri A, Abuelgasim Mohamedsalih TM, Mahmoud A, Mohamed Salih Abdelrahman MA, et al. Serum Galectin-3 and risk stratification in chronic heart failure: a systematic review of mortality outcomes. Cureus 2025; 17(6): e86959. doi: 10.7759\/cureus.86959. PMID: 40734851; PMCID: PMC12306356;","DOI":"10.7759\/cureus.86959"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Traub J, Schuhmann MK, Sell R, Frantz S, Stork S, Stoll G, et al. S100B serum levels in chronic heart failure patients: a multifaceted biomarker linking cardiac and cognitive dysfunction. Int J Mol Sci 2024; 25(16): 9094. doi: 10.3390\/ijms25169094. PMID: 39201780; PMCID: PMC11354705;","DOI":"10.3390\/ijms25169094"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wu L, Li X , Qian X , Wang S, Liu J, Yan J. Lipid nanoparticle (LNP) delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. Vaccines (Basel) 2024; 12(2): 186. doi: 10.3390\/vaccines12020186. PMID: 38400169; PMCID: PMC10891594;","DOI":"10.3390\/vaccines12020186"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Armentaro G, Condoleo V, Pastura CA, Grasso M, Frasca A, Martire D, et al. Prognostic role of serum albumin levels in patients with chronic heart failure. Intern Emerg Med 2024; 19(5): 1323-33. doi: 10.1007\/s11739-024-03612-9. Epub 2024 May 22. PMID: 38776047; PMCID: PMC11364577;","DOI":"10.1007\/s11739-024-03612-9"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Zheng YY, Wu TT, Hou XG , Yang HT, Yang Y, Xiu WJ, et al. Serum a-1 antitrypsin as a novel biomarker in chronic heart failure. ESC Heart Fail 2023; 10(5): 2865-74. doi: 10.1002\/ehf2.14451. Epub 2023 Jul 7. PMID: 37417425; PMCID: PMC10567649;","DOI":"10.1002\/ehf2.14451"},{"key":"ref34","unstructured":"Ni F, Xiang Y. Correlation between serum cystatin C and lipid level in patients with chronic heart failure. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2023; 48(1): 34-9. English, Chinese. doi: 10.11817\/j.issn.1672-7347.2023.220025. PMID: 36935175; PMCID: PMC10930551;"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Xie L, Zhou Z, Chen HX, Yan XY, Ye JQ, Jiang Y, Zhou L, et al. Correlations between serum laminin level and severity of heart failure in patients with chronic heart failure. Front Cardiovasc Med 2023; 10: 1089304. doi: 10.3389\/fcvm.2023.1089304. PMID: 37008313; PMCID: PMC10060624;","DOI":"10.3389\/fcvm.2023.1089304"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Wu L, Chen X , Zeng Q, Lai Z, Fan Z, Ruan X , et al. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon 2024; 10(7): e28282. doi: 10.1016\/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709;","DOI":"10.1016\/j.heliyon.2024.e28282"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Amaechi UM, Aiwuyo HO, Ewelukwa C, Ilerhunmwuwa N, Osarenkhoe JO, et al. Assessing iron status in chronic heart failure patients by using serum ferritin and transferrin saturation levels: a cross-sectional descriptive study. Cureus 2023; 15(5): e39425. doi: 10.7759\/cureus.39425. PMID: 37362450; PMCID: PMC10288524;","DOI":"10.7759\/cureus.39425"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Matin SS, Shidfar F Naderi N, Amin A, Hosseini-Baharanchi FS, Dehnad A. The impact of synbiotic on serum sCD163\/sTWEAK, paraoxonase 1, and lipoproteins in patients with chronic heart failure: a randomised, triple-blind, controlled trial. Sci Rep 2024; 14(1): 19120. doi: 10.1038\/s41598-024-69560-8. PMID: 39155305; PMCID: PMC11330970;","DOI":"10.1038\/s41598-024-69560-8"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Korelacija nivoa serumskog NT-pro-BNP IGFBP-7 i CTRP12 kod pacijenata sa hroni\u010dnom sr\u010danom insuficijencijom"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582605014F.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:42:54Z","timestamp":1779432174000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582605014F"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-61393","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}